Header Logo

Connection

GEORGE R BLUMENSCHEIN to Adult

Back to Details
This is a "connection" page, showing publications GEORGE R BLUMENSCHEIN has written about Adult.
GEORGE R BLUMENSCHEIN
Connection Strength
0.517
Adult
  1. Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2019 05; 20(3):e362-e368.
    View in: PubMed
    Score: 0.025
  2. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015 May; 37(5):644-9.
    View in: PubMed
    Score: 0.019
  3. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)?. Ann Oncol. 2015 May; 26(5):894-901.
    View in: PubMed
    Score: 0.019
  4. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). Ann Oncol. 2013 09; 24(9):2382-9.
    View in: PubMed
    Score: 0.017
  5. Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study. J Thorac Oncol. 2012 Sep; 7(9):1406-16.
    View in: PubMed
    Score: 0.016
  6. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer. 2013 Jan 01; 119(1):7-15.
    View in: PubMed
    Score: 0.016
  7. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol. 2011 Jun 10; 29(17):2312-8.
    View in: PubMed
    Score: 0.015
  8. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2011 Sep; 22(9):2057-2067.
    View in: PubMed
    Score: 0.015
  9. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res. 2010 Jan 01; 16(1):279-90.
    View in: PubMed
    Score: 0.014
  10. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs. 2008 Feb; 26(1):81-7.
    View in: PubMed
    Score: 0.012
  11. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 09 09; 402(10405):871-881.
    View in: PubMed
    Score: 0.009
  12. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol. 2022 04; 23(4):540-552.
    View in: PubMed
    Score: 0.008
  13. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol. 2021 08; 5.
    View in: PubMed
    Score: 0.008
  14. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
    View in: PubMed
    Score: 0.007
  15. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153. J Clin Oncol. 2020 11 20; 38(33):3863-3873.
    View in: PubMed
    Score: 0.007
  16. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. J Clin Oncol. 2020 06 01; 38(16):1824-1835.
    View in: PubMed
    Score: 0.007
  17. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. J Thorac Oncol. 2019 11; 14(11):1901-1911.
    View in: PubMed
    Score: 0.007
  18. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer. 2019 09 15; 125(18):3208-3218.
    View in: PubMed
    Score: 0.007
  19. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019 09 01; 25(17):5221-5230.
    View in: PubMed
    Score: 0.007
  20. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 06 20; 37(18):1558-1565.
    View in: PubMed
    Score: 0.006
  21. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2019 03 01; 30(3):471-477.
    View in: PubMed
    Score: 0.006
  22. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clin Cancer Res. 2018 06 15; 24(12):2771-2779.
    View in: PubMed
    Score: 0.006
  23. Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy. Clin Cancer Res. 1997 Dec; 3(12 Pt 2):2633-7.
    View in: PubMed
    Score: 0.006
  24. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer. 2017 Sep 12; 17(1):646.
    View in: PubMed
    Score: 0.006
  25. Effects of short-term in vivo administration of G-CSF on bone marrow prior to harvesting. Exp Hematol. 1997 Jan; 25(1):34-8.
    View in: PubMed
    Score: 0.006
  26. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced?Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 03; 12(3):556-566.
    View in: PubMed
    Score: 0.005
  27. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682.
    View in: PubMed
    Score: 0.005
  28. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 11 10; 375(19):1856-1867.
    View in: PubMed
    Score: 0.005
  29. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26; 7(17):23227-38.
    View in: PubMed
    Score: 0.005
  30. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2462-70.
    View in: PubMed
    Score: 0.005
  31. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015 Feb; 16(2):187-99.
    View in: PubMed
    Score: 0.005
  32. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014 Oct 15; 5(19):8937-46.
    View in: PubMed
    Score: 0.005
  33. EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. Radiother Oncol. 2014 Jul; 112(1):30-6.
    View in: PubMed
    Score: 0.005
  34. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013 Nov 10; 31(32):4105-14.
    View in: PubMed
    Score: 0.004
  35. Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer. 2013 Oct; 13(5):378-84.
    View in: PubMed
    Score: 0.004
  36. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013 Apr; 8(4):436-42.
    View in: PubMed
    Score: 0.004
  37. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52.
    View in: PubMed
    Score: 0.004
  38. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013 Jan; 24(1):220-5.
    View in: PubMed
    Score: 0.004
  39. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012 Apr 15; 18(8):2269-77.
    View in: PubMed
    Score: 0.004
  40. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
    View in: PubMed
    Score: 0.004
  41. Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults. Head Neck. 2012 Sep; 34(9):1255-62.
    View in: PubMed
    Score: 0.004
  42. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53.
    View in: PubMed
    Score: 0.004
  43. Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. Clin Lung Cancer. 2011 Jul; 12(4):212-7.
    View in: PubMed
    Score: 0.004
  44. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemother Pharmacol. 2011 Sep; 68(3):703-12.
    View in: PubMed
    Score: 0.004
  45. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer. 2010 May 15; 116(10):2409-15.
    View in: PubMed
    Score: 0.003
  46. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res. 2010 Mar 15; 16(6):1938-49.
    View in: PubMed
    Score: 0.003
  47. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs. 2011 Jun; 29(3):499-505.
    View in: PubMed
    Score: 0.003
  48. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):775-81.
    View in: PubMed
    Score: 0.003
  49. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol. 2008 Apr; 3(4):351-7.
    View in: PubMed
    Score: 0.003
  50. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol. 2007 Nov; 31(11):1645-52.
    View in: PubMed
    Score: 0.003
  51. High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. J Clin Oncol. 1987 Feb; 5(2):178-84.
    View in: PubMed
    Score: 0.003
  52. Second neoplasms after adjuvant chemotherapy for operable breast cancer. Am J Clin Oncol. 1986 Jun; 9(3):269-75.
    View in: PubMed
    Score: 0.003
  53. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986 May; 46(5):2578-81.
    View in: PubMed
    Score: 0.003
  54. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer. 2006 Mar; 7(5):326-31.
    View in: PubMed
    Score: 0.003
  55. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. 2005 Dec 01; 104(11):2449-56.
    View in: PubMed
    Score: 0.003
  56. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol. 2005 Dec 20; 23(36):9089-96.
    View in: PubMed
    Score: 0.003
  57. Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy. Cancer. 1985 Nov 15; 56(10):2381-4.
    View in: PubMed
    Score: 0.003
  58. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer. 2005 Aug 15; 104(4):682-91.
    View in: PubMed
    Score: 0.003
  59. Five-day continuous-infusion vinblastine in the treatment of breast cancer. Cancer. 1985 Jul 15; 56(2):225-9.
    View in: PubMed
    Score: 0.002
  60. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer. 1985 Jun 15; 55(12):2761-5.
    View in: PubMed
    Score: 0.002
  61. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005 Apr 10; 23(11):2544-55.
    View in: PubMed
    Score: 0.002
  62. A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma. Cancer. 1985 Jan 15; 55(2):337-40.
    View in: PubMed
    Score: 0.002
  63. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1985; 5(3):321-6.
    View in: PubMed
    Score: 0.002
  64. High-dose 1-beta-D-arabinofuranosylcytosine in advanced breast cancer. Oncology. 1985; 42(5):273-4.
    View in: PubMed
    Score: 0.002
  65. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. Semin Oncol. 1984 Sep; 11(3 Suppl 1):28-31.
    View in: PubMed
    Score: 0.002
  66. Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone. Cancer Treat Rep. 1984 Jul-Aug; 68(7-8):1039-41.
    View in: PubMed
    Score: 0.002
  67. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol. 2004 Oct; 54(4):308-14.
    View in: PubMed
    Score: 0.002
  68. Radiation-induced breast cancer. Arch Intern Med. 1984 Jun; 144(6):1217-9.
    View in: PubMed
    Score: 0.002
  69. Phase I-II study of high-dose mitomycin with autologous bone marrow transplantation in refractory metastatic breast cancer. Cancer Treat Rep. 1984 May; 68(5):805-6.
    View in: PubMed
    Score: 0.002
  70. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone. Cancer. 1984 May 01; 53(9):1841-4.
    View in: PubMed
    Score: 0.002
  71. Tumor-associated fever in breast cancer. Cancer. 1984 Apr 01; 53(7):1596-9.
    View in: PubMed
    Score: 0.002
  72. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1369-77.
    View in: PubMed
    Score: 0.002
  73. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer. 2003 Nov 15; 98(10):2214-23.
    View in: PubMed
    Score: 0.002
  74. Benign versus malignant hepatic lesions. A diagnostic dilemma with breast cancer patients. Cancer. 1983 Oct 01; 52(7):1308-11.
    View in: PubMed
    Score: 0.002
  75. Cranial nerve palsies in metastatic breast cancer due to osseous metastasis without intracranial involvement. Cancer. 1983 Jul 01; 52(1):180-4.
    View in: PubMed
    Score: 0.002
  76. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):17-21.
    View in: PubMed
    Score: 0.002
  77. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5.
    View in: PubMed
    Score: 0.002
  78. Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer. Cancer Treat Rep. 1983 Jun; 67(6):599-600.
    View in: PubMed
    Score: 0.002
  79. Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy. Int J Radiat Oncol Biol Phys. 1983 May; 9(5):643-50.
    View in: PubMed
    Score: 0.002
  80. Osteoblastic metastatic disease as a therapeutic response to adjuvant chemotherapy in breast cancer. J Surg Oncol. 1983 May; 23(1):32-4.
    View in: PubMed
    Score: 0.002
  81. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA. 1983 Apr 08; 249(14):1881-6.
    View in: PubMed
    Score: 0.002
  82. Hormonal therapy for metastatic male breast cancer. Arch Intern Med. 1983 Feb; 143(2):237-40.
    View in: PubMed
    Score: 0.002
  83. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol. 2002 Nov 15; 20(22):4440-7.
    View in: PubMed
    Score: 0.002
  84. Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. Cancer. 1982 Nov 01; 50(9):1708-12.
    View in: PubMed
    Score: 0.002
  85. Phase II trial of bruceantin in metastatic breast carcinoma. Am J Clin Oncol. 1982 Aug; 5(4):389-91.
    View in: PubMed
    Score: 0.002
  86. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer. 2002 Jul 15; 95(2):340-53.
    View in: PubMed
    Score: 0.002
  87. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer. 1982 Feb 01; 49(3):413-7.
    View in: PubMed
    Score: 0.002
  88. Combination chemotherapy for breast cancer metastatic to bone marrow. Cancer. 1981 Jul 15; 48(2):227-32.
    View in: PubMed
    Score: 0.002
  89. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer. 1981 Jun 15; 47(12):2798-802.
    View in: PubMed
    Score: 0.002
  90. Management of inflammatory carcinoma of breast with combined modality approach - an update. Cancer. 1981 Jun 01; 47(11):2537-42.
    View in: PubMed
    Score: 0.002
  91. Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP). Cancer Treat Rep. 1981 Jan-Feb; 65(1-2):33-8.
    View in: PubMed
    Score: 0.002
  92. Treatment of herniating subdural hematoma. JAMA. 1980 Dec 19; 244(24):2728-9.
    View in: PubMed
    Score: 0.002
  93. Causes of death in breast cancer: a clinicopathologic study. Cancer. 1980 Jul 01; 46(1):162-7.
    View in: PubMed
    Score: 0.002
  94. Human lymphocyte blastogenesis responses to mouse mammary tumor virus. J Natl Cancer Inst. 1980 Mar; 64(3):425-30.
    View in: PubMed
    Score: 0.002
  95. Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma. Cancer. 1980 Feb 15; 45(4):742-9.
    View in: PubMed
    Score: 0.002
  96. Pulmonary toxicity of mitomycin. Cancer. 1980 Jan 15; 45(2):236-44.
    View in: PubMed
    Score: 0.002
  97. The natural history of breast cancer patients with brain metastases. Cancer. 1979 Nov; 44(5):1913-8.
    View in: PubMed
    Score: 0.002
  98. Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. JAMA. 1979 Jul 06; 242(1):49-52.
    View in: PubMed
    Score: 0.002
  99. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res. 1979 May; 39(5):1552-62.
    View in: PubMed
    Score: 0.002
  100. Rubidazone in metastatic breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):135-6.
    View in: PubMed
    Score: 0.002
  101. Endobronchial metastases in breast carcinoma. West J Med. 1978 Sep; 129(3):177-80.
    View in: PubMed
    Score: 0.002
  102. Meningeal carcinomatosis in breast cancer. Cancer. 1978 Jul; 42(1):283-6.
    View in: PubMed
    Score: 0.002
  103. Adriamycin and mitomycin C: possible synergistic cardiotoxicity. Cancer Treat Rep. 1978 Jul; 62(7):1005-8.
    View in: PubMed
    Score: 0.002
  104. Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer. 1978 Jun; 41(6):2084-7.
    View in: PubMed
    Score: 0.002
  105. Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial. Mol Biother. 1992 Mar; 4(1):4-9.
    View in: PubMed
    Score: 0.001
  106. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol. 1991 Jul; 9(7):1233-40.
    View in: PubMed
    Score: 0.001
  107. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol. 1987 Mar; 5(3):354-64.
    View in: PubMed
    Score: 0.001
  108. Phase II study of AMSA and doxorubicin to treat metastatic breast cancer. Oncology. 1986; 43(4):205-7.
    View in: PubMed
    Score: 0.001
  109. A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1986; 18(2):157-61.
    View in: PubMed
    Score: 0.001
  110. Trioxifene mesylate in the treatment of advanced breast cancer. Cancer. 1986 Jan 01; 57(1):40-3.
    View in: PubMed
    Score: 0.001
  111. Effect of cyclophosphamide on the mitomycin-induced syndrome of thrombotic thrombocytopenic purpura. Cancer Treat Rep. 1985 May; 69(5):565-6.
    View in: PubMed
    Score: 0.001
  112. Management of inflammatory carcinoma of the breast. A combined modality approach. Am J Clin Oncol. 1985 Apr; 8(2):134-41.
    View in: PubMed
    Score: 0.001
  113. Induction chemotherapy of breast cancer. Prog Clin Biol Res. 1985; 201:105-16.
    View in: PubMed
    Score: 0.001
  114. The management of locally advanced breast cancer: a combined modality approach. Eur J Cancer Clin Oncol. 1984 Nov; 20(11):1353-61.
    View in: PubMed
    Score: 0.001
  115. Phase II study of spirogermanium in the treatment of metastatic breast cancer. Cancer Treat Rep. 1984 Sep; 68(9):1197-8.
    View in: PubMed
    Score: 0.001
  116. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. Cancer. 1984 May 01; 53(9):1836-40.
    View in: PubMed
    Score: 0.001
  117. Carminomycin. A new anthracycline analog in the treatment of advanced breast cancer. Cancer. 1984 Jan 01; 53(1):9-12.
    View in: PubMed
    Score: 0.001
  118. Combination chemotherapy with cyclophosphamide, mitoxantrone and 5-fluorouracil in patients with metastatic breast cancer. Cancer Treat Rev. 1983 Dec; 10 Suppl B:53-5.
    View in: PubMed
    Score: 0.001
  119. Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer. Cancer. 1983 Mar 01; 51(5):769-72.
    View in: PubMed
    Score: 0.001
  120. Multimodal treatment of locoregionally advanced breast cancer. Cancer. 1983 Mar 01; 51(5):763-8.
    View in: PubMed
    Score: 0.001
  121. Bisantrene, an active new drug in the treatment of metastatic breast cancer. Cancer Res. 1983 Mar; 43(3):1402-4.
    View in: PubMed
    Score: 0.001
  122. Phase II clinical evaluation of AZQ in metastatic breast cancer. Am J Clin Oncol. 1983 Feb; 6(1):31-3.
    View in: PubMed
    Score: 0.001
  123. Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer. Am J Clin Oncol. 1982 Oct; 5(5):511-4.
    View in: PubMed
    Score: 0.001
  124. AMSA and peptichemio in the treatment of advances metastatic breast cancer: a phase II study. Am J Clin Oncol. 1982 Aug; 5(4):383-7.
    View in: PubMed
    Score: 0.001
  125. Potential cardiotoxicity with mitoxantrone. Cancer Treat Rep. 1982 Aug; 66(8):1641-3.
    View in: PubMed
    Score: 0.001
  126. Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene). Cancer Treat Rep. 1982 Jul; 66(7):1517-20.
    View in: PubMed
    Score: 0.001
  127. Phase II trail of PCNU in refractory advanced breast cancer. Am J Clin Oncol. 1982 Jun; 5(3):249-51.
    View in: PubMed
    Score: 0.001
  128. Peptichemio versus melphalan (L-PAM) in advanced breast cancer. Cancer. 1982 May 01; 49(9):1767-70.
    View in: PubMed
    Score: 0.000
  129. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer. 1982 May 01; 49(9):1762-6.
    View in: PubMed
    Score: 0.000
  130. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982 Feb; 96(2):133-9.
    View in: PubMed
    Score: 0.000
  131. Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat. 1982; 2(2):163-9.
    View in: PubMed
    Score: 0.000
  132. Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Ann Intern Med. 1981 Dec; 95(6):694-7.
    View in: PubMed
    Score: 0.000
  133. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):775-9.
    View in: PubMed
    Score: 0.000
  134. Phase II evaluation of methyl-GAG in patients with refractory metastatic breast cancer. Cancer Treat Rep. 1981 May-Jun; 65(5-6):465-7.
    View in: PubMed
    Score: 0.000
  135. Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma. Cancer. 1981 Mar 15; 47(6):1369-76.
    View in: PubMed
    Score: 0.000
  136. Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy. J Surg Oncol. 1981; 18(2):163-72.
    View in: PubMed
    Score: 0.000
  137. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med. 1980 Sep; 93(3):399-406.
    View in: PubMed
    Score: 0.000
  138. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep. 1980 Feb-Mar; 64(2-3):279-83.
    View in: PubMed
    Score: 0.000
  139. Strategy for evaluation of a new antitumor agent in the treatment of breast cancer. Recent Results Cancer Res. 1980; 70:153-7.
    View in: PubMed
    Score: 0.000
  140. Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med. 1979 Dec; 91(6):847-52.
    View in: PubMed
    Score: 0.000
  141. Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):2053-6.
    View in: PubMed
    Score: 0.000
  142. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer. 1979 Nov; 44(5):1955-62.
    View in: PubMed
    Score: 0.000
  143. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):1961-4.
    View in: PubMed
    Score: 0.000
  144. Diabetes insipidus and breast cancer. Arch Intern Med. 1979 Sep; 139(9):1009-11.
    View in: PubMed
    Score: 0.000
  145. Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer. Cancer. 1979 Aug; 44(2):398-405.
    View in: PubMed
    Score: 0.000
  146. Male breast cancer: a natural history study. Cancer. 1979 Aug; 44(2):748-54.
    View in: PubMed
    Score: 0.000
  147. Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer. Cancer. 1979 Jul; 44(1):32-4.
    View in: PubMed
    Score: 0.000
  148. Phase II study of anguidine in advanced breast cancer. Cancer Treat Rep. 1979 May; 63(5):789-91.
    View in: PubMed
    Score: 0.000
  149. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer. 1979 Apr; 43(4):1225-33.
    View in: PubMed
    Score: 0.000
  150. Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. J Surg Oncol. 1979; 11(4):325-32.
    View in: PubMed
    Score: 0.000
  151. Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):115-20.
    View in: PubMed
    Score: 0.000
  152. Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):77-83.
    View in: PubMed
    Score: 0.000
  153. Thyroid-stimulating hormone and prolactin levels in breast cancer. Arch Intern Med. 1978 Nov; 138(11):1638-41.
    View in: PubMed
    Score: 0.000
  154. Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Gu?rin. Cancer Treat Rep. 1978 Nov; 62(11):1685-92.
    View in: PubMed
    Score: 0.000
  155. Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma. Cancer Treat Rep. 1978 Oct; 62(10):1565-7.
    View in: PubMed
    Score: 0.000
  156. Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer. Cancer. 1978 Apr; 41(4):1235-9.
    View in: PubMed
    Score: 0.000
  157. Etiologic factors of hypercalcemia in breast cancer. Tex Med. 1978 Mar; 74(3):52-5.
    View in: PubMed
    Score: 0.000
  158. Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer. 1978 Mar; 41(3):1064-75.
    View in: PubMed
    Score: 0.000
  159. Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy. Cancer. 1978 Feb; 41(2):392-5.
    View in: PubMed
    Score: 0.000
  160. Chemo immunotherapy of advanced breast cancer with BCG. Recent Results Cancer Res. 1977; (62):143-50.
    View in: PubMed
    Score: 0.000
  161. Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. Br Med J. 1976 Nov 20; 2(6046):1222-5.
    View in: PubMed
    Score: 0.000
  162. Phase I studies with Baker's Antifol (BAF) (NSC 139105). Cancer. 1976 Aug; 38(2):690-4.
    View in: PubMed
    Score: 0.000
  163. Mucocutaneous candidiasis, anergy and a plasma inhibitor of cellular immunity: reversal after amphotericin B therapy. Clin Exp Immunol. 1971 Nov; 9(5):595-602.
    View in: PubMed
    Score: 0.000
  164. Familial paraproteinemia. Arch Intern Med. 1971 Sep; 128(3):427-31.
    View in: PubMed
    Score: 0.000
  165. A new type of human gamma heavy chain disease protein: immunochemical and physical characteristics. Immunochemistry. 1970 Apr; 7(4):373-81.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.